GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: hPT3 [3] | JNJ-3657 | JNJ-63733657 | JNJ3657 | JNJ63733657
Compound class:
Antibody
Comment: Posdinemab (JNJ-63733657) is a humanized IgG1/kappa monoclonal antibody that targets phosphorylated microtubule-associated protein tau. It binds to phosphorylated threonine residues in the protein's proline-rich domain. JNJ-63733657 was humanized from mouse parental antibody PT3 [3]. Phospho-tau reduction is proposed for the treatment of Alzheimer's disease.
|
| References |
|
1. Galpern WR, Triana-Baltzer G, Li L, Van Kolen K, Timmers M, Haeverans K, Janssens L, Kolb H, Nandy P, Aida K et al.. (2024)
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease. J Prev Alzheimers Dis, 11 (6): 1592-1603. [PMID:39559872] |
|
2. Mullard A. (2024)
Anti-tau antibody stumbles in phase II Alzheimer trial. Nat Rev Drug Discov, 23 (12): 883. [PMID:39487218] |
|
3. Van Kolen K, Malia TJ, Theunis C, Nanjunda R, Teplyakov A, Ernst R, Wu SJ, Luo J, Borgers M, Vandermeeren M et al.. (2020)
Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody. J Alzheimers Dis, 77 (4): 1397-1416. [PMID:32894244] |
|
4. Wang F, Liu J, Bai D, Li L, Fedgchin M, Henley D, Li H, Zhang F. (2025)
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Posdinemab (JNJ-63733657) in Healthy Chinese Adults. J Clin Pharmacol, [Epub ahead of print]. [PMID:41078145] |
